Gerresheimer Opens a Representative Office in India

By Gerresheimer Ag, PRNE
Monday, November 8, 2010

Gerresheimer Steps Up Business Operations in Emerging Markets

DUSSELDORF, Germany, November 9, 2010 - Gerresheimer AG, one of the world's leading suppliers to the
pharma and healthcare industry, is still expanding its global operations. The
establishment of a representative office in Mumbai/India reflects the
company's commitment to the strategy of profiting from the consistent growth
in emerging markets.

Gerresheimer intends to advance its very promising
pharmaceutical primary packaging and drug delivery systems business in the
growth market of India. In addition to sales operations, the company is also
stepping up its local customer services and technical services.

"Our strategic objective is to achieve above average growth in
the emerging markets. We currently generate around ten percent of our
revenues in these dynamically growing markets and we aim to double this
figure over the next three years. Opening our representative office in India
is an important step towards achieving this objective," said Uwe Rohrhoff,
CEO of Gerresheimer AG.

Alongside China, where Gerresheimer already has seven production
facilities, the fast-growing Indian pharma market is continually gaining in
significance. There is incessant growth of demand for medicines in India. One
reason for this is the improvement of the Indian healthcare system, which
gives people greater access to medications. International pharmaceutical
groups are now also manufacturing more products in India for other regions.
Leading market research institutes expect above average growth rates in
emerging nation pharma markets over coming years.

About Gerresheimer

Gerresheimer is a leading manufacturer of high quality
specialty glass and plastic products for the international pharmaceuticals
and healthcare industries. Our comprehensive portfolio of products extends
from pharmaceutical vials to complex drug delivery systems such as syringe
systems, insulin pens and inhalers for safe medication dosage and
application. Together with our partners, we develop solutions which set
standards and have role model status in their respective market sectors.

Our Group has production operations at 40 sites in Europe,
North and South America and Asia. It realizes sales of around one billion
and has 9,500 employees. We use first-rate technologies, convincing
innovations and targeted investments to systematically consolidate our strong
market position.

    Media contact

    Jens Kurten
    Director Corporate Communication & Marketing
    Telephone +49-211-6181-250
    Telefax +49-211-6181-241

    Investor Relations contact
    Anke Linnartz
    Director Investor Relations
    Telephone +49-211-6181-314
    Telefax +49-211-6181-121

Media contact: Jens Kurten, Director Corporate Communication & Marketing, Telephone +49-211-6181-250, Telefax +49-211-6181-241, E-Mail j.kuerten at; Investor Relations contact: Anke Linnartz, Director Investor Relations, Telephone +49-211-6181-314, Telefax +49-211-6181-121, E-Mail a.linnartz at

will not be displayed